Homocysteinylated fibrinogen forms disulfide-linked complexes with albumin

Thrombosis Research

Volumn 127, Issue 6, 2011, Pages 576-581

  Sauls, Derrick L ^a,b   Warren, Maria ^c   Hoffman, Maureane ^a,b  

^a DURHAM VA MEDICAL CENTER   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF NORTH CAROLINA   (United States)

Author keywords

Dysfibrinogenemia; Fibrinogen; Fibrinolysis; Homocysteine; Thrombosis

Indexed keywords

ALBUMIN; DISULFIDE; FIBRINOGEN; HEMOGLOBIN; HOMOCYSTEINE; PLASMINOGEN;

ARTICLE; BLOOD CLOTTING; CONJUGATION; CONTROLLED STUDY; FIBRIN CLOT; FIBRINOLYSIS; HUMAN; HYPERGLYCEMIA; PRIORITY JOURNAL; PROTEIN INTERACTION;

ALBUMINS; ANIMALS; BLOTTING, WESTERN; DISULFIDES; FIBRINOGEN; HOMOCYSTEINE; HUMANS; HYPERHOMOCYSTEINEMIA; RABBITS;

EID: 79957615453     PISSN: 00493848     EISSN: 18792472     Source Type: Journal    
DOI: 10.1016/j.thromres.2011.01.009     Document Type: Article

References (32)

1. McCully KS. Vascular pathology of homocysteinemia: implications for the pathogenesis of arteriosclerosis. Am J Pathol 1969;56(1):111-28.
2. McQuillan BM, Beilby JP, Nidorf M, Thompson PL, Hung J. Hyperhomocysteinemia but not the C677T mutation of methylenetetrahydrofolate reductase is an independent risk determinant of carotid wall thickening. The Perth Carotid Ultrasound Disease Assessment Study (CUDAS). Circulation 1999;99(18):2383-8. (Pubitemid 29218232)
3. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease. Probable benefits of increasing folic acid intakes. JAMA 1995;274(13):1049-57.
4. Nevado Jr JB, Imasa MS. Homocysteine predicts adverse clinical outcomes in unstable angina and non-ST elevation myocardial infarction: implications from the folate intervention in non-ST elevation myocardial infarction and unstable angina study. Coron Artery Dis 2008;19(3):153-61. (Pubitemid 351555968)
5. Shammas NW, Dippel EJ, Jerin M, Toth PP, Kapalis M, Reddy M, et al. Elevated levels of homocysteine predict cardiovascular death, nonfatal myocardial infarction, and symptomatic bypass graft disease at 2-year follow-up following coronary artery bypass surgery. Prev Cardiol 2008;11(2):95-9.
6. Aronson DC, OnkenhoutW, Raben AM, Oudenhoven LF, Brommer EJ, van Bockel JH. Impaired homocysteine metabolism: a risk factor in young adults with atherosclerotic arterial occlusive disease of the leg. Br J Surg 1994;81(8):1114-8. (Pubitemid 24262931)
7. Sauls DL, Wolberg AS, Hoffman M. Elevated plasma homocysteine leads to alterations in fibrin clot structure and stability: implications for the mechanism of thrombosis in hyperhomocysteinemia. J Thromb Haemost 2003;1(2):300-6.
8. Sauls DL, Arnold EK, Bell CW, Allen JC, Hoffman M. Pro-thrombotic and pro-oxidant effects of diet-induced hyperhomocysteinemia. Thromb Res 2007;120(1):117-26. (Pubitemid 46628705)
9. Lauricella AM, Quintana I, Castanon M, Sassetti B, Kordich L. Influence of homocysteine on fibrin network lysis. Blood Coagul Fibrinolysis 2006;17(3):181-6.
10. Undas A, Brozek J, Jankowski M, Siudak Z, Szczeklik A, Jakubowski H. Plasma homocysteine affects fibrin clot permeability and resistance to lysis in human subjects. Arterioscler Thromb Vasc Biol 2006;26(6):1397-404. (Pubitemid 44305388)
11. Undas A, Plicner D, Stepien E, Drwila R, Sadowski J. Altered fibrin clot structure in patients with advanced coronary artery disease: a role of C-reactive protein, lipoprotein(a) and homocysteine. J Thromb Haemost 2007;5(9):1988-90. (Pubitemid 47288965)
12. Hoffman M. Alterations of fibrinogen structure in human disease. Cardiovasc Hematol Agents Med Chem 2008;6(3):206-11.
13. Marchi R, Carvajal Z, Weisel JW. Comparison of the effect of different homocysteine concentrations on clot formation using human plasma and purified fibrinogen. Thromb Haemost 2008;99(2):451-2. (Pubitemid 351230980)
14. Rojas AM, Kordich L, Lauricella AM. Homocysteine modifies fibrin clot deformability: another possible explanation of harm. Biorheology 2009;46(5):379-87.
15. Haverkate F, SamamaM. Familial dysfibrinogenemia and thrombophilia. Report on a study of the SSC Subcommittee on Fibrinogen. Thromb Haemost 1995;73(1):151-61.
16. Jakubowski H. Homocysteine thiolactone: metabolic origin and protein homocysteinylation in humans. J Nutr 2000;130(2S Suppl):377S-81S.
17. Leanza WJ, Chupak LS, Tolman RL, Marburg S. Acidic derivatives of homocysteine thiolactone: utility as anionic linkers. Bioconjug Chem 1992;3(6):514-8.
18. Hop CE, Bakhtiar R. Homocysteine thiolactone and protein homocysteinylation: mechanistic studies with model peptides and proteins. Rapid Commun Mass Spectrom 2002;16(11):1049-53. (Pubitemid 34555905)
19. Jakubowski H. Protein homocysteinylation: possible mechanism underlying pathological consequences of elevated homocysteine levels. FASEB J 1999;13(15): 2277-83.
20. Sauls DL, Lockhart E, Warren ME, Lenkowski A, Wilhelm SE, Hoffman M. Modification of fibrinogen by homocysteine thiolactone increases resistance to fibrinolysis: a potential mechanism of the thrombotic tendency in hyperhomocysteinemia. Biochemistry 2006;45(8):2480-7.
21. Undas A, Perla J, Lacinski M, Trzeciak W, Kazmierski R, Jakubowski H. Autoantibodies against N-homocysteinylated proteins in humans: implications for atherosclerosis. Stroke 2004;35(6):1299-304. (Pubitemid 38697447)
22. Yang X, Gao Y, Zhou J, Zhen Y, Yang Y, Wang J, et al. Plasma homocysteine thiolactone adducts associated with risk of coronary heart disease. Clin Chim Acta 2006;364(1-2):230-4. (Pubitemid 43120647)
23. Undas A, Stepien E, Glowacki R, Tisonczyk J, Tracz W, Jakubowski H. Folic acid administration and antibodies against homocysteinylated proteins in subjects with hyperhomocysteinemia. Thromb Haemost 2006;96(3):342-7. (Pubitemid 44377819)
24. Mosesson MW. Fibrinogen structure and fibrin clot assembly. Semin Thromb Hemost 1998;24(2):169-74. (Pubitemid 28180828)
25. Medved L, Nieuwenhuizen W. Molecular mechanisms of initiation of fibrinolysis by fibrin. Thromb Haemost 2003;89(3):409-19. (Pubitemid 36329229)
26. Marchi R, Mirshahi SS, Soria C, Mirshahi M, Zohar M, Collet JP, et al. Thrombotic dysfibrinogenemia. Fibrinogen "Caracas V" relation between very tight fibrin network and defective clot degradability. Thromb Res 2000;99(2):187-93.
27. Sedlak J, Lindsay RH. Estimation of total, protein-bound, and nonprotein sulfhydryl groups in tissue with Ellman's reagent. Anal Biochem 1968;25(1):192-205.
28. Furlan M. Purification of fibrinogen. Curr Probl Clin Biochem 1984;14:133-45.
29. Walker JB, Nesheim ME. The molecular weights, mass distribution, chain composition, and structure of soluble fibrin degradation products released from a fibrin clot perfused with plasmin. J Biol Chem 1999;274(8):5201-12.
30. Maruyama T, Katoh S, Nakajima M, Nabetani H. Mechanism of bovine serum albumin aggregation during ultrafiltration. Biotechnol Bioeng 2001;75(2):233-8. (Pubitemid 32937295)
31. Koopman J, Haverkate F, Grimbergen J, Engesser L, Novakova I, Kerst A, et al. Abnormal fibrinogens IJmuiden (B beta Arg14 - Cys) and Nijmegen (B beta Arg44 - Cys) form disulfide-linked fibrinogen-albumin complexes. Proc Natl Acad Sci USA 1992;89(8):3478-82.
32. Koopman J, Haverkate F, Grimbergen J, Lord ST, Mosesson MW, DiOrio JP, et al. Molecular basis for fibrinogen Dusart (A alpha 554 Arg->Cys) and its association with abnormal fibrin polymerization and thrombophilia. J Clin Invest 1993;91(4): 1637-43. (Pubitemid 23127367)